Market closed
Y-mAbs/YMAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Y-mAbs
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Ticker
YMAB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
100
Website
Y-mAbs Metrics
BasicAdvanced
$612M
Market cap
-
P/E ratio
-$0.56
EPS
0.65
Beta
-
Dividend rate
Price and volume
Market cap
$612M
Beta
0.65
52-week high
$20.90
52-week low
$4.69
Average daily volume
296K
Financial strength
Current ratio
2.916
Quick ratio
2.3
Long term debt to equity
0.453
Total debt to equity
1.336
Management effectiveness
Return on assets (TTM)
-12.50%
Return on equity (TTM)
-24.61%
Valuation
Price to revenue (TTM)
6.948
Price to book
6.36
Price to tangible book (TTM)
6.53
Price to free cash flow (TTM)
-47.9
Growth
Revenue change (TTM)
1.84%
Earnings per share change (TTM)
-37.11%
3-year revenue growth (CAGR)
32.64%
3-year earnings per share growth (CAGR)
-17.94%
What the Analysts think about Y-mAbs
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Y-mAbs stock.
Y-mAbs Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Y-mAbs Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Y-mAbs News
AllArticlesVideos
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research
GlobeNewsWire·1 week ago
Y-mAbs to Participate in Upcoming Investor Conferences in September
GlobeNewsWire·2 weeks ago
Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Y-mAbs stock?
Y-mAbs (YMAB) has a market cap of $612M as of September 15, 2024.
What is the P/E ratio for Y-mAbs stock?
The price to earnings (P/E) ratio for Y-mAbs (YMAB) stock is 0 as of September 15, 2024.
Does Y-mAbs stock pay dividends?
No, Y-mAbs (YMAB) stock does not pay dividends to its shareholders as of September 15, 2024.
When is the next Y-mAbs dividend payment date?
Y-mAbs (YMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Y-mAbs?
Y-mAbs (YMAB) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.